Full-Time

Business Development Representative

Business Development

Updated on 7/21/2026

Zeiss

Zeiss

1,001-5,000 employees

Corporate venture capital for deep-tech startups

No salary listed

Company Does Not Provide H1B Sponsorship

Michigan, USA

Remote

Resident within Michigan territory; ideally near Detroit, Lansing, or Flint.

Category
Business & Strategy (1)
Required Skills
Salesforce

Get referred to Zeiss

Find people who can refer or advise you

Requirements
  • Must have a valid driver’s license.
  • Demonstrated ability to be proficient with standard MS Office applications and company technology devices (Laptop, iPad, iPhone, etc.) for territory management and product orders.
  • Excellent verbal and written communication skills.
  • Excellent interpersonal, problem-solving, and analytical skills.
  • Demonstrated ability to operate as a team player and to work collaboratively with and through others.
  • Ability to influence situations and people.
  • Self-starter with the ability to work independently.
  • Demonstrated ability to move key opportunities through the sales cycle by providing detailed and accurate sales forecasts using the company’s CRM tool.
Responsibilities
  • Meet or exceed sales growth targets for Direct Rx business and other strategic targets such as premium lenses, coatings, dispensing tools and equipment, or key sales programs.
  • Segment territory using CRM Account Classification system and identifying key customer targets to increase territory sales.
  • Profile and evaluate each customer’s store operation, financial data, business model & profit drivers, and create value-based sales strategies that have positive financial impact on company.
  • Conduct and prepare pre-call planning and call objectives and anticipate likely objections; understand motivations and establish a relationship as a trusted advisor / consultant.
  • Lead sales conversation with Eye Care Professionals by challenging and persuading them to change behavior. Build agreement at each point in the sales process, remove barriers and close the deal.
  • Create innovative tactical and strategic approaches to meet and exceed business objectives when faced with an obstacle or a customer concern.
  • Treat territory as own franchise by creating and executing territory plan to achieve goals; consider required investment and financial impact in developing customer strategies.
  • Increase sales by effectively communicating the advantages and benefits of Carl Zeiss Vision products and services to Eye Care Professionals.
  • Support and implement national marketing plans, utilizing digital tools and apps.
  • Schedule, plan, develop and conduct on-site individual, group and office training and educational seminars to increase demand for Carl Zeiss Vision labs, lenses, and dispensing tools.
  • Maximize and execute customer marketing programs to accomplish goals and objectives.
  • Establish a positive, productive and collaborative working relationship with Carl Zeiss Vision employees and colleagues.
  • Operate with the highest ethical standard during every customer interaction and in alignment with Carl Zeiss philosophies and leadership principles.
  • Input accurate and timely reports via Salesforce.com.
  • Efficiently manage travel cost and leverage smart spending techniques.
  • Prepare and submit timely expense reports.
Desired Qualifications
  • BS or BA in Business, Public Administration, Marketing, or related field strongly preferred.
  • 2+ years in a successful business to business sales environment, preferably in Rx sales, optical, medical device, or retail operations industry with Fortune 500 companies strongly preferred.
  • ABO and/or optical experience preferred.
  • Knowledge of Salesforce.com preferred.

ZEISS Ventures is the corporate venture capital arm of the ZEISS Group, investing in deep-tech startups in Information Technology, Industrial Tech, MedTech, and Life Sciences. It backs early-stage companies at pre-Series A to Series A with typical investments of $1–5 million. The fund provides capital and tailored funding solutions, leveraging ZEISS’s global network and optics/optoelectronics expertise to support portfolio companies. Its goal is to accelerate the development of new technologies and business models that complement ZEISS’s portfolio while actively engaging with external innovation.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$65.3M

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Custom Surgical targets analog ophthalmology workflows with digital standardization.[4]
  • Maculaser advances non-damaging retinal therapy for earlier intervention and vision preservation.[5]
  • ZEISS can commercialize external innovation through its global optics and healthcare footprint.[2]

What critics are saying

  • Clinical trials can fail, stopping Maculaser’s retinal therapy before commercialization.[5]
  • Ophthalmology digitization faces slow hospital adoption and entrenched analog workflows.[4]
  • Deep-tech medtech concentrates regulatory and reimbursement risk across ZEISS Ventures’ portfolio.[2]

What makes Zeiss unique

  • ZEISS Ventures backs deep-tech startups relevant to ZEISS’s core businesses.[2]
  • It targets pre-Series A and Series A companies with 500k–5 million euro tickets.[2]
  • Its focus spans Industrial Tech, Med Tech, and Life Sciences with ZEISS network access.[2]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Performance Bonus

Company News

PR Newswire
Apr 2nd, 2026
ZEISS unveils AI-powered patient platform and enhanced IOL tools at ASCRS

ZEISS has unveiled new digital, AI and surgical innovations for cataract and refractive workflows at the ASCRS conference. The medical technology company is expanding its US cataract portfolio with new irrigation/aspiration handpieces compatible with the DORC EVA NEXUS surgical system, alongside enhanced IOL calculation capabilities for the ZEISS IOLMaster 700. ZEISS also launched VisioGen commercially in the US, a human-verified AI patient engagement platform for ophthalmology practices. The platform integrates with clinic websites to capture patient demand around the clock, with AI-assisted responses reviewed by ZEISS-trained optometrists before delivery. The company showcased ZEISS Collaborative Care, a cloud-based application enabling secure data sharing between eye care professionals, and previewed ZEISS CLINIC 360, pending FDA clearance. ZEISS is celebrating 100 years of US operations this year.

PR Newswire
Mar 24th, 2026
ZEISS expands ophthalmic portfolio in Canada with new diagnostic lasers and workflow tools

ZEISS Medical Technology has expanded its ophthalmic workflow portfolio in Canada with new diagnostic, visualisation and therapeutic solutions. The company will showcase the innovations at upcoming Canadian ophthalmology conferences in Ottawa and Montréal. Key additions include ICGA for ZEISS CLARUS 700, offering simultaneous FA and ICG capture for clinical assessment, and ZEISS VISULAS green with selective laser trabeculoplasty for retinal photocoagulation. The company has introduced refraction devices ZEISS VISUREF 600 and ZEISS VISUCORE 500 to streamline diagnostic workflows. ZEISS also launched VISULAS yag, a new-generation therapeutic laser for anterior segment photodisruption within cataract workflows. The ZEISS FORUM subscription package, now available in Canada, offers integrated data management with unlimited device licences and lower upfront costs.

PR Newswire
Feb 23rd, 2026
ZEISS launches Collaborative Care app for eye care professionals with cloud and on-premises options

ZEISS Medical Technology has launched Collaborative Care, a browser-based application enabling eye care professionals to share data securely, refer patients and coordinate clinical care. Built on the ZEISS Health Data Platform, the solution addresses fragmented data sharing and inefficient referral processes in ophthalmic care. The application offers flexible deployment as either a standalone cloud solution or an integrated extension of ZEISS FORUM. Key features include secure exchange of images and reports, streamlined referral workflows with tracking capabilities, and tools for building professional networks between optometrists and ophthalmologists. ZEISS Collaborative Care was demonstrated at industry events in London and Orlando in February and March 2026. The company generated €2,228 million in revenue in fiscal year 2024/25 with 5,784 employees worldwide.

Handelsblatt
Feb 19th, 2026
Custom Surgical raises $4M to develop AI-powered ophthalmology platform

Custom Surgical, a German ophthalmology company, has raised €3.5 million to advance its platform. The funding will support development of AI-powered features including automated image optimisation and assisted triage processes that help determine case urgency and specialist assignment. The company is already developing its first AI-based triage and screening system. The technology aims to provide initial assessments that guide decisions on how urgently cases need attention and which medical professionals should handle them next.

Investors Hangout
Feb 18th, 2026
Mindpeak raises $15.3M Series A to scale AI cancer diagnostic tools

Mindpeak, an AI-driven pathology startup, raised $15.3 million in a Series A round led by ZEISS Ventures and InnoVentureFund in 2024. The funding will accelerate development and deployment of the company's AI diagnostic tools for cancer pathology. Founded in 2018, Mindpeak's algorithms have supported over 30,000 patient diagnoses across US and European healthcare markets. The technology uses automated histological analyses to help pathologists make faster, more precise clinical decisions. CEO Felix Faber stated the capital would expedite product rollouts and expand capabilities. The company has established strategic partnerships with major players including Roche. Mindpeak operates in the rapidly growing digital pathology market, driven by technological innovation and increasing demand for advanced diagnostic services in an ageing population.